These findings suggest that the activation of oncogenic signaling pathways related to cell proliferation, adhesion, cancer stemness, and a noninflammatory tumor microenvironment are associated with the risk of recurrence in early-stage HER2-positive breast cancer [20]. This evidence concerns the gene ERBB2 and cancer.